进展性特发性肺纤维化中III型和VI型胶原高转换
在185例新诊断的特发性肺纤维化(IPF)患者中,检测III型和VI型胶原转换的新表位生物标志物(C3M、C6M、PRO-C3、PRO-C6)。基线C3M、C6M、PRO-C3、PRO-C6升高与诊断时更晚期疾病相关;C6M和PRO-C3与3年死亡率相关;多种标志物升高者短期进展或死亡风险及3年死亡率更高。
要点
- 基线C3M、C6M、PRO-C3和PRO-C6升高与IPF诊断时更晚期疾病相关。
- 基线C6M和PRO-C3升高与3年随访死亡率相关。
- 多种生物标志物升高提示高ECM转换表型,与短期进展和长期死亡高风险相关。
核心结论
- 诊断时检测的III型和VI型胶原转换血液生物标志物与IPF疾病严重程度、短期进展和长期死亡率相关。
- 这些标志物有助于识别高ECM转换表型、高疾病进展和死亡风险的患者。
研究设计与样本
- 研究纳入185例新诊断的IPF患者,检测III型和VI型胶原转换的新表位生物标志物(C3M、C6M、PRO-C3和PRO-C6)。
- 基线疾病严重程度和6个月进展通过肺功能测试和6分钟步行测试评估;全因死亡率随访3年。
主要发现
- 基线C3M、C6M、PRO-C3和PRO-C6高水平与诊断时更晚期疾病相关。
- 基线C6M和PRO-C3与3年随访死亡率相关(HR: 2.3, 95% CI: 1.3-3.9, p = 0.002 和 HR: 1.8, 95% CI: 1.1-3.0, p = 0.03)。
- 基线多种生物标志物升高(高ECM转换表型)者基线疾病更晚期,6个月进展或死亡风险更高(OR: 1.4, 95% CI: 1.1-1.8, p = 0.002),3年随访死亡率更高(HR: 2.4, 95% CI: 1.3-4.5, p = 0.007)。
临床怎么用
- 在IPF诊断时检测III型和VI型胶原转换血液生物标志物,可辅助识别高疾病进展和死亡风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Prediction of idiopathic pulmonary fibrosis (IPF) progression is vital for the choice and timing of treatment and patient follow-up. This could potentially be achieved by prognostic blood biomarkers of extracellular matrix (ECM) remodelling. METHODS: Neoepitope biomarkers of types III and VI collagen turnover (C3M, C6M, PRO-C3 and PRO-C6) were measured in 185 patients with newly diagnosed IPF. Disease severity at baseline and progression over 6 months was assessed by lung function tests and 6-min walk tests. All-cause mortality was assessed over a 3-year follow-up period. RESULTS: High baseline levels of C3M, C6M, PRO-C3 and PRO-C6 were associated with more advanced disease at the time of diagnosis. Baseline levels of C6M and PRO-C3 were also associated with mortality over 3 years of follow-up (hazard ratio [HR]: 2.3, 95% CI: 1.3-3.9, p = 0.002 and HR: 1.8, 95% CI: 1.1-3.0, p = 0.03). Patients with several increased biomarkers at baseline, representing a high ECM remodelling phenotype, had more advanced disease at baseline, higher risk of progression or death at 6 months (OR: 1.4, 95% CI: 1.1-1.8, p = 0.002) and higher mortality over 3 years of follow-up (HR: 2.4, 95% CI: 1.3-4.5, p = 0.007). CONCLUSION: Blood biomarkers of types III and VI collagen turnover, assessed at the time of diagnosis, are associated with several indices of disease severity, short-term progression and long-term mortality. These biomarkers can help to identify patients with a high ECM remodelling phenotype at high risk of disease progression and death.
引用
- Hoyer N, Jessen H, Prior TS, et al. High turnover of types III and VI collagen in progressive idiopathic pulmonary fibrosis. Respirology. 2021. PMID: 33834579. doi:10.1111/resp.14056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。